- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about edit
Recent news which mentions edit
Tickers
EDIT
From Motley Fool
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 15, 2023
From Benzinga
2 Short-Squeeze Candidates That Could Go Parabolic
June 15, 2023
From Motley Fool
Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 15, 2023
From Benzinga
From Benzinga
5 Stocks to Buy With Explosive 500% Potential
June 12, 2023
From InvestorPlace
Editas' Gene Editing Treatment Shows Initial Safety, Efficacy In Patients With Rare Blood Disorders
June 09, 2023
Tickers
EDIT
From Benzinga
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
June 06, 2023
From InvestorPlace
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial
June 01, 2023
From Benzinga
7 Short-Squeeze Stocks Set for a May Rally
May 22, 2023
From InvestorPlace
From Motley Fool
ONEOK, PacWest Bancorp And Other Big Stocks Moving Lower In Monday's Pre-Market Session
May 15, 2023
From Benzinga
Earnings Scheduled For May 5, 2023
May 05, 2023
From Benzinga
The 3 Most Promising Gene Editing Stocks to Buy in 2023
April 28, 2023
From InvestorPlace
Why Shares of Editas Medicine Rose Monday
April 17, 2023
From Motley Fool
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 17, 2023
From Benzinga
2 Stocks Under $15 Per Share to Consider
April 16, 2023
From Motley Fool
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
April 13, 2023
From InvestorPlace
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 13, 2023
From Benzinga
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
April 13, 2023
From Benzinga
From Motley Fool
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
April 06, 2023
From Motley Fool
Tickers
EDIT
From Motley Fool
Tickers
EDIT
From Motley Fool
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.